Teva Pharmaceutical Industries Limited (TEVA)
Pre-Market:
| Previous Close | 16.78 |
| Open | 16.79 |
| Bid | 15.93 x 1300 |
| Ask | 16.23 x 4000 |
| Day's Range | 16.10 - 16.87 |
| 52 Week Range | 7.09 - 17.13 |
| Volume | |
| Avg. Volume | 10,191,267 |
| Market Cap | 18.903B |
| Beta (5Y Monthly) | 1.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Nov 27, 2017 |
| 1y Target Est | N/A |
- Business Wire
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
TEL AVIV, Israel, May 15, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company’s manufacturing and supply division, effective June 3, 2024. Mr. Shields succeeds Eric Drapé, who is leaving after 11 years with the Company, including more than four years as Executive Vice President, Global Operations. Mr. Shields will be a member of Teva’s Executive Leadership Team
- Business Wire
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
TEL AVIV, Israel, May 08, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2024.
- Business Wire
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS, May 08, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), today announced results from the efficacy portion of the Phase 3 Subcutaneous OLAnzapine extended-Release Injection Study (SOLARIS) trial evaluating TEV-‘749 in adult patients with schizophrenia compared to placebo. Results demonstrated that TEV-‘749 met its primary endpoint as measured by a change in the
